Pure Global
NCT06420284

Immunological Parameters Between MRONJ Stages

Characterization of Immunological Parameters in Different Clinical Stages of Medication-Related Osteonecrosis of the Jaw
Marmara University·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Medication-Related Osteonecrosis of Jaw
Study type
Observational
Sponsor & location
Primary sponsor
Marmara University
Location
Istanbul, Turkey
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
May 01, 2025
Enrollment
42 participants
Primary outcome

Lymphocyte Proliferation Analysis,Apoptosis Analysis in Lymphocytes,Cytokine Profile Analysis

Summary

This study aims to conduct a detailed analysis of the immunological response profiles that
 emerge at different clinical stages of medication-related osteonecrosis of the jaw (MRONJ).
 The research seeks to understand how these responses influence the pathogenesis, staging, and
 treatment of MRONJ. Throughout the study, cytokine levels, inflammation markers, and other
 immunological parameters observed at various stages will be comprehensively assessed. The
 results of these analyses are expected to provide insights into how stage-specific
 immunological variables could play a role in the diagnosis and treatment of MRONJ.

ICD-10 classifications
Osteonecrosis due to drugsOsteonecrosisOsteonecrosis, unspecifiedOther osteonecrosisOsteonecrosis in other diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06420284
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06420284 through Pure Global AI's free database. This phase not specified trial is sponsored by Marmara University and is currently Recruiting. The study focuses on Medication-Related Osteonecrosis of Jaw. Target enrollment is 42 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.